Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience Wi...(or severe arm edema with placebo comp...),Health

compared to 17% with HYLENEX (p < 0.0001).

AEs occurring following treatment were mild to moderate in severity,

localized to the infusion sites, and evenly distributed between placebo

and HYLENEX treatment arms. There were no severe or serious AEs.

In the double-blinded global preference ranking, both study subjects and

the Investigator preferred, in 92% of cases across the three dose cohorts,

the HYLENEX-assisted arms for Sub-Q infusions rather than placebo arms

(p < 0.0001).

The Journal of Palliative Medicine is an interdisciplinary journal that reports on the clinical, educational, legal, and ethical aspects of care for seriously ill and dying patients. It includes coverage of the latest developments in drug and non-drug treatments for patients with life-threatening diseases. The journal reports on the development of palliative care programs around the U.S. and the world and innovation in palliative care education.

HYLENEX is a liquid injectable drug product formulation that includes the active pharmaceutical ingredient recombinant human hyaluronidase (rHuPH20) and is approved by the U.S. Food and Drug Administration (FDA) for use as a spreading agent to increase the absorption and dispersion of other injected drugs and for Sub-Q fluid administration. HYLENEX is the first and only FDA-approved hyaluronidase from a recombinant human source. Sub-Q hydration is the introduction of fluids under the skin to replace inadequate intake or excessive loss of water and electrolytes during illness or operation.

About HYLENEX

HYLENEX recombinant (hyaluronidase human injection, rHuPH20) is indicated as an adjuvant to increase the absorption and dispersion of other injected drugs, as an adjuvant for subcutaneous fluid administration (hypodermoclysis), and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents. Hyaluronidase is contraindi
'/>"/>